Fig. 4

Association of ADAM6 and PRSS1 with classical prognostic markers in acute leukemia patients, and their correlation with each other. A Serum ADAM6 levels in CD22⁻ (n = 21) versus CD22⁺ (n = 15) ALL patients. B Serum ADAM6 levels in CD45⁻ (n = 21) versus CD45⁺ (n = 15) ALL patients. C Serum PRSS1 levels in HLA-DR⁻ (n = 32) versus HLA-DR⁺ (n = 4) ALL patients. D Spearman correlation analyses of serum ADAM6 and PRSS1 in all the study cohort, including acute leukemia patients and control subjects (n = 131). Box plots represent the interquartile range, the line inside the box represents the median, and the bars represent the minimum and maximum values. Shown p-Values are for Mann–Whitney test. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ADAM6, A Disintegrin And Metalloproteinase Domain-6; PRSS1, Serine protease 1; CD, cluster of differentiation; HLA-DR, human leucocyte antigen death receptor